To evaluate patients with uveitis, a tailored multimodal imaging approach can be very helpful both in the clinic and in clinical trials. With selective imaging, you can integrate and correlate the data from different images for a more conclusive diagnosis.
Tocilizumab, a recombinant humanized, antihuman monoclonal antibody, can be effective in improving visual acuity and reducing vitreous haze in patients with noninfectious uveitis, according to a recent study.
JIA-associated uveitis is a challenging inflammatory condition in the pediatric population. Adalimumab was found to be effective and safe in reducing ocular imflammation within 2 months and well tolerated over 12 months in JIA-associated uveitis.
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
Adalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.
At the 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, about 100 uveitis and uveitis-related papers and posters were presented by researchers from around the world. The presentations covered a wide range of research initiatives that are underway to treat–or at least understand how to address–uveitis. Here are five intriguing abstracts of research that were presented at the meeting.